TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
The purpose of this study:

To explore the comparative effectiveness of BIBF 1120 in terms of :

* Progression-free survival (PFS), objective response, overall survival
* Evaluate and compare safety
Colorectal Cancer
DRUG: mFOLFOX6 + BIBF 1120|DRUG: mFOLFOX6+placebo
progression free survival, 1 year
The purpose of this study:

To explore the comparative effectiveness of BIBF 1120 in terms of :

* Progression-free survival (PFS), objective response, overall survival
* Evaluate and compare safety